Department of Human Structure and Repair, Ghent University, B-9000 Ghent, Belgium; Department of GI Surgery, Ghent University Hospital, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
Peter MacCallum Cancer Centre and the Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
Trends Cancer. 2020 Mar;6(3):236-246. doi: 10.1016/j.trecan.2019.12.008. Epub 2020 Jan 16.
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (IP) delivery of chemotherapy, is limited. Increasingly, therefore, efforts are being developed to unravel the PM cascade and at understanding the PM-associated tumor microenvironment (TME) and peritoneal ecosystem as potential therapeutic targets. Here, we review recent insights in the structure and components of the TME in colorectal PM, and discuss how these may translate into novel therapeutic approaches aimed at re-engineering the metastasis-promoting activity of the stroma.
腹膜转移(PM)发生在大约四分之一的结直肠癌(CRC)患者中。CRC 腹膜转移的病理生理学仍未得到充分描述。此外,包括手术和腹腔内(IP)化疗给药在内的当前治疗方式的疗效有限。因此,人们越来越努力揭开 PM 级联反应的奥秘,并了解 PM 相关的肿瘤微环境(TME)和腹膜生态系统作为潜在的治疗靶点。在这里,我们回顾了结直肠癌 PM 中 TME 的结构和组成的最新见解,并讨论了这些如何转化为旨在重新设计基质促进转移活性的新型治疗方法。